Precocious puberty means sexual maturation begins before age 8 in girls. This can include breast budding, pubic or underarm hair, a growth spurt, body odor, acne, or vaginal bleeding. The timing matters more than one isolated symptom.

It is estimated to affect about 1 in 5,000 to 10,000 children. Doctors in many countries, including India, are seeing more early puberty referrals. Better nutrition, rising childhood obesity, and possible environmental chemical exposure may partly explain this increase.

Central precocious puberty is the more common type in girls. It is GnRH-dependent, meaning the brain starts the normal puberty pathway too early. The ovaries then begin making estrogen, so the pattern usually looks like normal puberty, just earlier.

Peripheral precocious puberty is less common. It is GnRH-independent and happens when hormones come from another source, such as an ovarian or adrenal tumor, congenital adrenal hyperplasia, or external estrogen exposure. Treatment depends on the cause, so this distinction matters.

Early signs include breast budding before 8, pubic hair before 8, a sudden growth spurt, body odor, acne, mood changes, or periods before age 10. Families should note when each sign first appeared and whether changes are moving quickly over months.

Not every sign means true precocious puberty. Pubic hair alone may reflect precocious adrenarche, a common benign variant. Isolated breast tissue can also be non-progressive. Tracking milestones helps the pediatric endocrinologist decide whether testing or watchful waiting is better.

Early estrogen exposure speeds bone maturation. That can close growth plates sooner than expected, so a child who seems tall early may end up shorter as an adult if fast-progressing puberty is not addressed.

There is also a psychosocial burden. A child may look older than she feels, face teasing, body-image stress, sexualization, or misunderstanding around periods. In some Indian families, early menstruation is wrongly praised as being "fast growing" instead of being treated as a pediatric issue.

Evaluation usually starts with a pediatric endocrinologist. The visit includes growth review, Tanner staging, and a timeline of symptoms. A bone age X-ray of the left hand and wrist, often around Rs 400 to 800, helps show whether bones are maturing too fast.

Blood tests may include LH, FSH, and estradiol. If basal values are unclear, a GnRH stimulation test helps confirm central puberty. Brain MRI, often around Rs 6,000 to 12,000, may be advised especially in younger girls or if there are neurologic symptoms, to rule out a tumor or other CNS lesion.

In Indian girls, the most common cause of central precocious puberty is idiopathic, meaning no dangerous structural cause is found. That is reassuring, but doctors still need to exclude less common causes when the child is very young or progression is rapid.

Other causes include CNS lesions, congenital adrenal hyperplasia, ovarian or adrenal hormone excess, and exogenous estrogen exposure from creams or other products. Obesity is also linked to earlier pubertal timing and is increasingly relevant in urban Indian settings. For broader nutrition context, see Vitamin D Deficiency in Indian Women: Why Seventy to Ninety Percent of Us Are Low, What to Test, and How to Treat It.

The right specialist is a pediatric endocrinologist, ideally an ISPAE member or someone working regularly with puberty disorders. A pediatrician may begin the referral, but treatment decisions about GnRH agonists should usually be made by pediatric endocrine teams.

In India, consultations at centers such as Apollo, Fortis, or Cloudnine often range from about Rs 800 to 3,000. Government hospitals and academic centers such as AIIMS may offer free or lower-cost care, though wait times can be longer. In tier-2 cities, referral to a tertiary center is often worth the trip.

If a girl has central precocious puberty that is clearly progressive, doctors may use GnRH agonists to pause further pubertal advancement until a more appropriate age. Common options in India include leuprolide, sold under brands such as Lupride or Eligard, and triptorelin, including Decapeptyl.

These medicines are usually given as depot injections, monthly or at longer intervals depending on the formulation. Treatment often continues for 2 to 3 years. It is considered safe and reversible, and future fertility is generally preserved because puberty restarts after treatment stops.

GnRH analog injections commonly cost around Rs 3,500 to 8,000 per month for leuprolide and about Rs 4,000 to 9,000 per dose for triptorelin, depending on brand, city, and formulation. Over a full course, families may spend roughly Rs 1 lakh to 3 lakh including visits and tests.

Costs can be lower in public hospitals, and some families may receive partial support through Ayushman Bharat or state-linked schemes. Access remains uneven, so families outside metros may need a tertiary center. Keeping receipts and asking hospital social workers about subsidies can help.

Medical treatment is only part of care. Children need simple, age-appropriate explanations about breasts, body odor, and periods. Parents should prepare schools for practical issues such as bathroom access, changing clothes, and protection from teasing or adult-like comments.

Family counseling can help when anxiety, shame, or conflict is high. In India, services such as iCall and Sangath may support caregivers and older children. Some families prefer a female pediatric endocrinologist or adolescent gynecologist for comfort, and that is a reasonable request. For period literacy later on, see Tracking Your Cycle Without Shame: A Step-by-Step Empowerment Guide.